Emergent BioSolutions

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

Retrieved on: 
星期一, 四月 22, 2024
Emergent BioSolutions, EBS, ID, Telephone, Webcast

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.

Key Points: 
  • GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.
  • Participants can access the conference call live via webcast .
  • To participate via telephone, please register in advance at this link .
  • A replay of the call can be accessed from the Investors page of Emergent’s website.

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

Retrieved on: 
星期四, 三月 28, 2024
FSA, U.S. FDA, Arm, Heroin, Risk, Education, Pharmacy, School, Naloxone, Policy, EBS, Flexible, House, Drug, OTC, CDC, Restaurant, Medicaid, National Safety Council, AED, HSA, FDA, Emergent BioSolutions, NSC, Medicine, Fentanyl, Pharmaceutical industry

Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.

Key Points: 
  • Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.
  • Since the OTC launch, NARCAN® Nasal Spray can be purchased at more than 32,000 mass drug, grocery, online retailers and e-commerce sites.
  • Emergent is working with retail partners to make it easy to find and access, however each retailer ultimately determines in-store product placement.
  • “That’s why we remain committed to increasing awareness of NARCAN® Nasal Spray availability.

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Retrieved on: 
星期一, 三月 25, 2024
Letter, Emergent, Risk, Patient, CGMP, Ethics, Classification, News, EBS, Life, NAI, Emergent BioSolutions, VAI, FDA, Food, Management

GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.

Key Points: 
  • GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.
  • Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).
  • “We will continue to put quality and compliance first in our manufacturing operations to ensure we’re delivering high quality products to our customers and patients.”
    The result of obtaining NAI status in Bayview is a continuation of Emergent’s strong commitment to quality and compliance.
  • In 2023, Emergent manufacturing facilities were successfully inspected by five regulatory agencies across the globe and five other inspectional bodies for 18 inspections, including three by the FDA that resulted in NAI or VAI status.

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

Retrieved on: 
星期四, 二月 29, 2024
EBS, ID, Webcast, Telephone, Emergent BioSolutions

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023.

Key Points: 
  • GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023.
  • Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks.
  • Participants can access the conference call live via webcast from the Investors page of Emergent’s website.
  • A replay of the call can be accessed from the Investors page of Emergent’s website.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Retrieved on: 
星期三, 二月 21, 2024
EBS, Immunization, Emergent BioSolutions, FDA, Growth, U.S. FDA, Life, Post-exposure prophylaxis, Public, Vaccine

Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.

Key Points: 
  • Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.
  • "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent,” said Zsolt Harsanyi, Ph.D., chairman of the Board of Directors.
  • “He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry.
  • “I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness.

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Retrieved on: 
星期四, 一月 11, 2024
EBS, Pre-exposure prophylaxis, Radiation, Emergent, Anthrax vaccine adsorbed, Anthrax, IDIQ, Emergent BioSolutions

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.

Key Points: 
  • GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.
  • The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033.
  • “As a part of our mission to protect and enhance lives, Emergent is proud to continue supporting and preparing our nation’s service members who have a high risk of exposure to anthrax bacteria by supplying BioThrax vaccine,” said Paul Williams, senior vice president, products head at Emergent.
  • “This new contract award is a testament to the importance of Emergent’s medical countermeasures portfolio, and we look forward to delivering on our commitments to the U.S. DoD.”
    Under the initial five-year IDIQ contract, there is a guaranteed purchase minimum of $20.1 million, with future orders estimated to be at least $20 million for each following year for a total award value up to $235.8 million.

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

Retrieved on: 
星期二, 十一月 28, 2023
Post-exposure prophylaxis, Partnership, Licensure, Government, FDA, Acquisition, Administration, Human services, Calendar, Public, Emergent BioSolutions, EBS, Safety, Anthrax, Development, Emergent, Vaccine

Deliveries are expected to begin this calendar year and be complete by the end of the first quarter of 2024.

Key Points: 
  • Deliveries are expected to begin this calendar year and be complete by the end of the first quarter of 2024.
  • Anthrax is considered a high-priority national security threat and has the potential for major public health impact.
  • In April 2022, Emergent submitted the Biologics License Application to the FDA for review, leading to approval and licensure in July 2023.
  • This latest contract option supplements previous contract procurements and supports the U.S. biodefense preparedness efforts.

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Retrieved on: 
星期五, 十一月 24, 2023
Form, Bank statement, Emergent BioSolutions, EBS, Emergent, Security (finance), Cryptocurrency

GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC).

Key Points: 
  • GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC).
  • Notices are routinely issued by the NYSE in such situations.
  • Under the NYSE’s rules, Emergent will have six months from November 9, 2023 to file the Form 10-Q with the SEC, and can regain compliance with the NYSE listing standards upon filing the Form 10-Q.
  • Because these items also affect subsequent period reporting, the Company must complete this work prior to finalizing its financial statements for the three and nine months ended September 30, 2023 and filing its third quarter Form 10-Q.

Microbial Agricultural Inoculants Market to increase by USD 243.73 million between 2023 to 2028, AquaBella Organic Solutions LLC, BASF SE, Bayer AG and more among key companies - Technavio

Retrieved on: 
星期五, 十二月 8, 2023
Agriculture, Seed, Bacillus firmus, BASF SE, IAB, Bayer, Fungus, BIO, Biology, Corteva, USD, Farmer, BASF, Novozymes, Pesticide, SE, FREE, Emergent BioSolutions, Wine, Plant, Geography

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- The microbial agricultural inoculants market size is expected to grow by USD 243.73 million from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 8, 2023 /PRNewswire/ -- The microbial agricultural inoculants market size is expected to grow by USD 243.73 million from 2023 to 2028.
  • Rising concerns over the use of chemical fertilizers and pesticides in agriculture are notably driving the microbial agricultural inoculants market.
  • However, factors such as a lack of awareness of microbial agricultural inoculants among farmers may impede market growth.
  • Microbial Agricultural Inoculants Market 2024-2028: Company Analysis
    BASF SE - The company offers microbial agricultural inoculants such as Poncho Votivo bio seeds made up of Bacillus microbial and Votivo prime made up of Bacillus firmus microbial, under its brand called BioSolutions.

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期三, 十一月 8, 2023
Emergent, NYSE, EBS, Life, Disclosure, Growth, Total revenue test, Public, Emergent BioSolutions, Pharmaceutical industry

Third Quarter 2023 Total Revenues of $271M, above the prior guidance range

Key Points: 
  • Third Quarter 2023 Total Revenues of $271M, above the prior guidance range
    GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023.
  • The selected financial results reported include limited third quarter and year-to-date results, as well as selected balance sheet and cash flow information.
  • We expect to complete this work in the near future.
  • As we look ahead, we plan to continue protecting against public health threats for years to come.”